Founding
members

Home - About - Founding members

Expert founding members and complementary

MIB relies on a powerful multidisciplinary network of public, economic, private and academic partners.

This network, which is MIB’s real strength, enables us to benefit from a multitude of skills, resources and expertise.

Thanks to the diversity and complementarity of its founders, MIB is positioned as a scientific and economic center of excellence on an international scale.

Laurent<br/>Baly

Laurent
Baly

President of SATT
Sud-Est

Denis<br/>Bertin

Denis
Bertin

Delegate Vice-President A*Midex France 2030 Coordinator

Hervé<br/>Brailly

Hervé
Brailly

Chairman of the Executive Board
Chief Operating Officer by intermediary

Jean-luc<br/>Chauvin

Jean-luc
Chauvin

Chairman of the CCI

Dr. Divi<br/>Cornec

Dr. Divi
Cornec

Inserm Research Director at Brest University Hospital

François<br/>Crémieux

François
Crémieux

General Manager of APHM

Nathalie<br/>De Preville

Nathalie
De Preville

Director of Partnerships, Laboratoires Servier

Pierre<br/>d’Epenoux

Pierre
d’Epenoux

CEO ImCheck Therapeutics

Emilie Garrido-Pradalie

Emilie Garrido-Pradalie

Director of Health Research and Rare Diseases at AP-HM

Arnaud<br/>Mercier

Arnaud
Mercier

Representative of Métropole Aix-Marseille

Dr. Daniel<br/>Olive

Dr. Daniel
Olive

MIB Project Scientific and Technical Manager

Antoine<br/>Petit

Antoine
Petit

CEO, CNRS

Jean-Philippe<br/>Potier

Jean-Philippe
Potier

Pr. Bruno<br/>Quesnel

Pr. Bruno
Quesnel

Director of Research and Innovation, French National Cancer Institute

Marie<br/>Roumieux

Marie
Roumieux

Scientific Operations Manager

Emilie<br/>Royer

Emilie
Royer

Managing Director, Eurobiomed

Jean-Philippe<br/>Tissier Seta

Jean-Philippe
Tissier Seta

OFU General Manager

Pr. Norbert<br/>Vey

Pr. Norbert
Vey

Managing Director, Institut Paoli-Calmettes

Our
partners

Our
partners

It's out of date to oppose public and private (...) We see that, in the face of the logic of silos, the time has come to work on a more unified, better endowed biomedical research.”

Emmanuel Macron
MIB is a perspective, a hope of seeing the disease recede and perhaps, one day, overcome.

Renaud Muselier
MIB will have a structuring effect on the region, placing it on the global biotechnology map as the benchmark for immunology. It's a fantastic step forward for this strategic economic sector, but above all it's a source of pride to see that Marseille will become the home of this global immunology cluster, a therapy that holds so much hope for so many patients.

Martine Vassal